RA Capital Management’s Rhythm Pharmaceuticals RYTM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $740M | Hold |
6,666,837
| – | – | 6.43% | 3 |
|
|
2026
Q1 | $580M | Hold |
6,666,837
| – | – | 6.14% | 3 |
|
|
2025
Q4 | $714M | Buy |
6,666,837
+985,478
| +17% | +$105M | 7.31% | 3 |
|
|
2025
Q3 | $574M | Buy |
5,681,359
+120,000
| +2% | +$11.1M | 7.07% | 2 |
|
|
2025
Q2 | $351M | Sell |
5,561,359
-523,053
| -9% | -$32M | 5.92% | 3 |
|
|
2025
Q1 | $322M | Hold |
6,084,412
| – | – | 5.38% | 3 |
|
|
2024
Q4 | $341M | Hold |
6,084,412
| – | – | 4.53% | 4 |
|
|
2024
Q3 | $319M | Hold |
6,084,412
| – | – | 3.68% | 5 |
|
|
2024
Q2 | $250M | Buy |
6,084,412
+754,000
| +14% | +$30.1M | 3.3% | 5 |
|
|
2024
Q1 | $231M | Hold |
5,330,412
| – | – | 2.94% | 6 |
|
|
2023
Q4 | $245M | Sell |
5,330,412
-345,655
| -6% | -$10.9M | 3.83% | 5 |
|
|
2023
Q3 | $130M | Hold |
5,676,067
| – | – | 2.56% | 7 |
|
|
2023
Q2 | $93.6M | Buy |
5,676,067
+160,000
| +3% | +$2.89M | 1.77% | 16 |
|
|
2023
Q1 | $98.4M | Hold |
5,516,067
| – | – | 2.23% | 15 |
|
|
2022
Q4 | $161M | Buy |
5,516,067
+45,000
| +0.8% | +$1.16M | 3.26% | 6 |
|
|
2022
Q3 | $134M | Buy |
5,471,067
+600,000
| +12% | +$11.2M | 2.86% | 7 |
|
|
2022
Q2 | $20.2M | Hold |
4,871,067
| – | – | 0.54% | 45 |
|
|
2022
Q1 | $56.1M | Hold |
4,871,067
| – | – | 1.22% | 23 |
|
|
2021
Q4 | $48.6M | Hold |
4,871,067
| – | – | 0.86% | 33 |
|
|
2021
Q3 | $63.6M | Hold |
4,871,067
| – | – | 0.88% | 33 |
|
|
2021
Q2 | $71.1M | Hold |
4,871,067
| – | – | 1.14% | 26 |
|
|
2021
Q1 | $104M | Buy |
4,871,067
+692,000
| +17% | +$20.1M | 1.56% | 17 |
|
|
2020
Q4 | $124M | Sell |
4,179,067
-961,341
| -19% | -$24.4M | 1.74% | 14 |
|
|
2020
Q3 | $111M | Sell |
5,140,408
-69,680
| -1% | -$1.6M | 2.04% | 12 |
|
|
2020
Q2 | $116M | Sell |
5,210,088
-212,224
| -4% | -$4.14M | 2.26% | 14 |
|
|
2020
Q1 | $82.5M | Hold |
5,422,312
| – | – | 2.61% | 13 |
|
|
2019
Q4 | $124M | Buy |
5,422,312
+2,000,000
| +58% | +$44.4M | 3.78% | 6 |
|
|
2019
Q3 | $73.9M | Buy |
3,422,312
+1,537,530
| +82% | +$33M | 4.4% | 7 |
|
|
2019
Q2 | $41.5M | Hold |
1,884,782
| – | – | 2.23% | 11 |
|
|
2019
Q1 | $51.7M | Sell |
1,884,782
-65,550
| -3% | -$1.88M | 2.23% | 13 |
|
|
2018
Q4 | $52.4M | Hold |
1,950,332
| – | – | 3.05% | 12 |
|
|
2018
Q3 | $56.9M | Buy |
1,950,332
+408,589
| +27% | +$12.9M | 3.04% | 12 |
|
|
2018
Q2 | $48.2M | Buy |
+1,541,743
| New | +$42.2M | 3.13% | 12 |
|
Other funds holding RYTM
BBA
PA
RA Capital Management's RYTM Position: Q2 2026 in Review
RA Capital Management held its Rhythm Pharmaceuticals (RYTM) position steady in Q2 2026 at 6,666,837 shares worth $740M. The position accounts for 6.43% of the portfolio, ranked #3.
RA Capital Management first reported a position in RYTM in Q2 2018 and has held it in 33 quarters since. 303 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.
- RA Capital Management held 6,666,837 shares of Rhythm Pharmaceuticals worth $740M as of Q2 2026.
- RA Capital Management left its Rhythm Pharmaceuticals share count unchanged in Q2 2026.
- Rhythm Pharmaceuticals made up 6.43% of RA Capital Management's portfolio in Q2 2026, its #3 holding.
- RA Capital Management first reported a position in Rhythm Pharmaceuticals in Q2 2018 and has held it in 33 quarters since.
- 303 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.
Based on RA Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.